


## (Rac)-Rotigotine-d<sub>3</sub> hydrochloride

<b>Cat. No.:</b>	HY-15394S1
<b>CAS No.:</b>	1215846-20-0
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>23</sub> D <sub>3</sub> ClNOS
<b>Molecular Weight:</b>	354.95
<b>Target:</b>	Isotope-Labeled Compounds
<b>Pathway:</b>	Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	(Rac)-Rotigotine-d <sub>3</sub> hydrochloride is a deuterium labeled (Rac)-Rotigotine (hydrochloride) (HY-15394). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT <sub>1A</sub> receptor, and an antagonist of the α <sub>2B</sub> -adrenergic receptor, with K <sub>i</sub> s of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D <sub>3</sub> receptor and D <sub>2</sub> , D <sub>5</sub> , D <sub>4</sub> receptors, and dopamine D <sub>1</sub> receptor.
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Wood M, et al. Rotigotine is a potent agonist at dopamine D<sub>1</sub> receptors as well as at dopamine D<sub>2</sub> and D<sub>3</sub> receptors. *Br J Pharmacol.* 2015 Feb;172(4):1124-35.
- [2]. Scheller D, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. *Naunyn Schmiedebergs Arch Pharmacol.* 2009 Jan;379(1):73-86.
- [3]. Fenu S, et al. In vivo dopamine agonist properties of rotigotine: Role of D<sub>1</sub> and D<sub>2</sub> receptors. *Eur J Pharmacol.* 2016 Oct 5;788:183-91.
- [4]. Radad K, et al. Neuroprotective effect of rotigotine against complex I inhibitors, MPP<sup>+</sup> and rotenone, in primary mesencephalic cell culture. *Folia Neuropathol.* 2014;52(2):179-86.
- [5]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019 Feb;53(2):211-246.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA